Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
H. pylori Eradication (Quadruple Therapy)
Treatment for Peptic ulcer disease
Typical Dosage: Standardized regimens (e.g., PPI BID, Bismuth QID, Metronidazole QID, Tetracycline QID for 10-14 days)
Effectiveness
88%
Safety Score
68%
Clinical Trials
14
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Standardized regimens (e.g., PPI BID, Bismuth QID, Metronidazole QID, Tetracycline QID for 10-14 days)
Time to Effect
10-14 days for eradication, weeks for ulcer healing
Treatment Duration
10-14 days for antibiotics/bismuth, PPI often continued for 2-4 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$300
Side Effect Mgmt:$50
Total Annual:$450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$511.36
Cost per Remission
$548.78
H. pylori Eradication (Quadruple Therapy) Outcomes
for Peptic ulcer disease
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+82%
Common Side Effects
Diarrhea
+15%
Nausea
+10%
Abdominal pain
+8%
Black stool/tongue (Bismuth)
+25%
Dysgeusia (Metronidazole, Clarithromycin)
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for H. pylori Eradication (Quadruple Therapy) in Peptic ulcer disease
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia
NCT07146594NOT YET RECRUITINGPHASE4
150 participants
INTERVENTIONAL
Started: Aug 20, 2025
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT07068607RECRUITINGPHASE4
400 participants
INTERVENTIONAL
Xi'an, China
Started: Apr 1, 2025
Completed Clinical Trials
12 completed trials for H. pylori Eradication (Quadruple Therapy) in Peptic ulcer disease
Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication
NCT02175901COMPLETEDPHASE4
215 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2014
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy
NCT02633930COMPLETEDPHASE4
566 participants
INTERVENTIONAL
Xi’an, China +1 more
Started: Dec 1, 2015
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
NCT01667718COMPLETEDPHASE4
161 participants
INTERVENTIONAL
Shanghai, China
Started: May 1, 2012
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
NCT02296021COMPLETEDPHASE4
612 participants
INTERVENTIONAL
Xi’an, China
Started: Nov 1, 2014
The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients
NCT02648659COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Started: Mar 2, 2016
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05237115COMPLETEDPHASE4
600 participants
INTERVENTIONAL
Xi’an, China
Started: May 5, 2020
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568COMPLETEDPHASE4
124 participants
INTERVENTIONAL
Xi'an, China
Started: Dec 1, 2022
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
NCT03050307COMPLETEDPHASE3
234 participants
INTERVENTIONAL
Hefei, China +80 more
Started: Apr 17, 2017
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04678492COMPLETEDPHASE4
658 participants
INTERVENTIONAL
Xi'an, China
Started: Dec 20, 2020
Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT06168084COMPLETEDPHASE4
688 participants
INTERVENTIONAL
Xi'an, China +1 more
Started: Jun 6, 2023
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03609892COMPLETEDPHASE4
658 participants
INTERVENTIONAL
Xi'an, China
Started: Aug 1, 2018
The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers
NCT03342456COMPLETEDPHASE4
184 participants
INTERVENTIONAL
Changsha, China +6 more
Started: Dec 13, 2017